Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published, but not on the effectiveness prediction of evogliptin. Aim: To reveal the clinical characteristics and...
Guardado en:
Autores principales: | Anna A. Mosikian, Alina Y. Babenko, Yulia A. Sevastyanova, Roman V. Drai, Evgenij V. Shlyakhto |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0cda49c2db13461287d49fbf760d288a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial
por: Alina Y. Babenko, et al.
Publicado: (2018) -
Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
por: Editorial team Diabetes Mellitus
Publicado: (2012) -
Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010) -
Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010) -
Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL
por: Marina Vladimirovna Shestakova
Publicado: (2011)